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Abstract
Background: The purpose of the study was to investigate a novel BRAF and CDK 4/6 inhibitor combination
therapy in a murine model of BRAF-V600-mutant human melanoma monitored by 18F–FDG-PET/CT and diffusion-
weighted MRI (DW-MRI).
Methods: Human BRAF-V600-mutant melanoma (A375) xenograft-bearing balb/c nude mice (n = 21) were imaged
by 18F–FDG-PET/CT and DW-MRI before (day 0) and after (day 7) a 1-week BRAF and CDK 4/6 inhibitor combination
therapy (n = 12; dabrafenib, 20 mg/kg/d; ribociclib, 100 mg/kg/d) or placebo (n = 9). Animals were scanned on a
small animal PET after intravenous administration of 20 MBq 18F–FDG. Tumor glucose uptake was calculated as the
tumor-to-liver-ratio (TTL). Unenhanced CT data sets were subsequently acquired for anatomic coregistration. Tumor
diffusivity was assessed by DW-MRI using the apparent diffusion coefficient (ADC). Anti-tumor therapy effects were
assessed by ex vivo immunohistochemistry for validation purposes (microvascular density – CD31; tumor cell
proliferation – Ki-67).
Results: Tumor glucose uptake was significantly suppressed under therapy (ΔTTLTherapy − 1.00 ± 0.53 vs. ΔTTLControl
0.85 ± 1.21; p < 0.001). In addition, tumor diffusivity was significantly elevated following the BRAF and CDK 4/6 inhibitor
combination therapy (ΔADCTherapy 0.12 ± 0.14 × 10
−3 mm2/s; ΔADCControl − 0.12 ± 0.06 × 10
−3 mm2/s; p < 0.001).
Immunohistochemistry revealed a significant suppression of microvascular density (CD31, 147 ± 48 vs. 287 ± 92;
p = 0.001) and proliferation (Ki-67, 3718 ± 998 vs. 5389 ± 1332; p = 0.007) in the therapy compared to the control group.
Conclusion: A novel BRAF and CDK 4/6 inhibitor combination therapy exhibited significant anti-angiogenic and
anti-proliferative effects in experimental human melanomas, monitored by 18F–FDG-PET/CT and DW-MRI.
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Background
The mitogen-activated protein kinase (MAPK) pathway
controls cell cycle progression, survival, and proliferation
in human cells [1, 2]. B-rapidly accelerated fibrosarcoma
(BRAF) gene mutations V600E/K were identified as key
drivers of oncogenesis in melanoma, as they lead to
overactivation of the MAPK pathway and uncontrolled
cell proliferation [2]. Thus, selective inhibition of the
BRAF gene emerged as a novel, targeted treatment regi-
men in advanced or unresectable melanoma [3, 4]. How-
ever, tumor response to BRAF inhibitor monotherapy
may be limited by intrinsic or acquired resistance [5–7].
Consequently, combination therapies of BRAF inhibitors
and additional therapeutics potentially overcoming re-
sistance were investigated in recent years [5, 8]. One
possible mechanism of acquired BRAF inhibitor resist-
ance is MAPK pathway activation via the mitogen-
activated extracellular signal-regulated kinase (MEK).
Co-targeting the MAPK pathway by a BRAF and MEK
inhibitor combination therapy yields high response rates
as well as prolonged overall and progression-free sur-
vival in advanced BRAF-mutant melanoma compared to
other available treatment strategies, including BRAF
inhibitor monotherapy [9]. A possible mechanism of
intrinsic BRAF inhibitor resistance is cyclin D1 overex-
pression with cyclin-dependent kinase (CDK) 4 muta-
tion/amplification [2, 5]. Cyclin D1 promotes cell cycle
progression by binding to CDK 4 and 6, which act as
downstream mediators of the MAPK pathway and regu-
late the cell cycle via the retinoblastoma tumor suppres-
sor protein [2, 5]. Yadav et al. recently demonstrated
that the selective inhibition of CDK 4/6 leads to tumor
growth regression in a BRAF inhibitor-resistant in vivo
model of human melanoma (A375) [10]. In 2017, based
on the results of the MONALEESA-2 trial, the U.S. Food
and Drug Administration approved the CDK 4/6 inhibi-
tor ribociclib combined with an aromatase inhibitor for
the treatment of advanced or metastatic, hormone
receptor-positive and human epidermal growth factor
receptor 2-negative breast cancer in postmenopausal
women [11]. The addition of a CDK 4/6 inhibitor to
BRAF inhibitor monotherapy represents a novel strategy
to overcome cyclin D1-dependent resistance. Dual inhib-
ition of the MAPK pathway by a BRAF and CDK 4/6 in-
hibitor combination therapy may thus be a promising
future therapy regimen in advanced melanoma.
Imaging plays a central role for the non-invasive tumor
response assessment in clinical oncology. Morphology-
based criteria of tumor response, e. g., RECIST (Response
Evaluation Criteria in Solid Tumors), provide a valuable
clinical tool to differentiate between partial/complete re-
sponse, progressive, and stable disease [12]. These criteria
are based on the number and size of tumor manifesta-
tions, which are commonly assessed by morphological
imaging modalities such as computed tomography (CT)
or magnetic resonance imaging (MRI). However, in con-
trast to traditional, primarily cytotoxic therapies, novel
targeted therapies exhibit only subtle effects on tumor size
[13]. Thus, morphology-based tumor response criteria are
of only limited applicability in targeted therapy regimens
[14]. Functional and molecular imaging modalities allow
for a non-invasive tumor characterization beyond morph-
ology, delivering information on tumor pathophysiology
such as tumor glucose metabolism (18F–fluorodeoxyglu-
cose positron emission tomography; 18F–FDG-PET)
and tumor cellularity (diffusion-weighted MRI; DW-
MRI). Both 18F–FDG-PET and DW-MRI demonstrated
their potential to generate non-invasive imaging
biomarkers of therapy response in melanoma under
targeted therapy [15–18].
As a proof of principle, the present study is a first ap-
proach to explore a selective CDK 4/6 inhibitor as novel
combination compound for dual inhibition of the MAPK
signal pathway in melanoma therapy. The aim of this ex-
perimental study was to close this gap of knowledge,
evaluating a novel BRAF and CDK 4/6 inhibitor combin-
ation therapy in a murine model of human BRAF-V600-
mutant melanoma using a multimodal imaging protocol
of 18F–FDG-PET/CT and DW-MRI. We hypothesized
that a BRAF and CDK 4/6 inhibitor combination therapy
exhibits significant anti-angiogenic and anti-proliferative
effects in experimental human melanomas in mice and
that the according alterations in tumor pathophysi-
ology can be non-invasively monitored by 18F–FDG-
PET/CT and DW-MRI in vivo validated by ex vivo
immunohistochemistry.
Methods
The experiments were performed in accordance with the
Guidelines for the Care and Use of Laboratory Animals
of the National Institutes of Health and with approval by
the Government Committee for Animal Research.
Animal model and experimental protocol
After diluting human melanoma cells (A375, ATCC®
CRL-1619™, CLS Cell Lines Service GmbH, Eppelheim,
Germany) in a total volume of 0.1 mL as a 1:1 solution
of phosphate buffered saline (PBS pH 7.4; GIBCO Life
Technologies, Darmstadt, Germany) and Matrigel™ (BD
Biosciences, San Jose, CA), 3 × 106 cells per mouse were
injected subcutaneously into the left abdominal flank of
n = 21 athymic balb/c nude mice (Charles River, Sulzfeld,
Germany). When tumors reached a diameter of 0.5 cm,
animals were randomly assigned to either the therapy
(n = 12) or the control group (n = 9). Imaging was per-
formed on day 0 (baseline) and day 7 (follow-up) using
a multimodal imaging protocol of 18F–FDG PET/CT
and DW-MRI. Imaging was performed under inhalation
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anesthesia (2.5% in 1.0 L 100% O2/min for induction,
1.5% in 1.0 L 100% O2/min for maintenance). Subse-
quently to the baseline scan, animals were treated daily
with either a combination of BRAF inhibitor dabrafenib
(20 mg/kg/day; Novartis AG, Basel, Switzerland) and
CDK4/6 inhibitor ribociclib (100 mg/kg/day; Novartis
AG, Basel, Switzerland) in the therapy group or a
volume-equivalent placebo solution (0.5% hydroxy-
methyl cellulose and 0.2% Tween-80 in ddH20) in the
control group. Immediately after follow-up imaging on
day 7, animals were sacrificed and tumors were
explanted and fixed in formalin for immunohistochemi-
cal analysis with regard to tumor microvascular density
(CD31) and tumor cell proliferation (Ki-67). Figure 1
provides an overview of the experimental protocol.
PET imaging
Small-animal PET was performed on a preclinical PET
scanner (Inveon μPET, Siemens Healthineers, Erlangen,
Germany). For hygienic reasons and allowing regulated
anesthesia delivery, mice were placed inside a custom-
built acrylic glass-imaging chamber in prone position.
45 min after manual intravenous injection of 20 MBq
(~100 μL) 18F–FDG per animal, a transmission scan
(15 min) was acquired for scatter and attenuation cor-
rection. Subsequently, PET list-mode data acquisition
was initiated from 60 to 90 min (30 min emission).
All PET data were post-processed on an Inveon
Acquisition Workplace (Siemens Healthineers,
Erlangen, Germany). Images were reconstructed as a
static image using OSEM 3D (4 iterations) and
MAP 3D (32 iterations) algorithm in a 256 × 256
matrix with a zoom value of 100% as described previ-
ously [19]. To calculate the metabolic tumor volume
(MTV), a PET/CT-guided volume of interest (VOI)
surrounding the tumor was drawn manually and a
threshold-value of 30% of the hottest voxels was ap-
plied. Background was determined as mean uptake in
a 9 mm3 VOI in the right liver lobe. Tumor-to-liver-
ratio (TTL, VOImaxtumor/VOImeanliver) was deter-
mined as a semiquantitative measurement of tumor
radiotracer accumulation before (day 0) and after
treatment (day 7). Figure 2 demonstrates the process
of PET/CT VOI selection.
After PET measurements, additional CT images were
acquired on a latest generation clinical CT (SOMATOM
Force, Siemens Healthineers, Erlangen, Germany), main-
taining the animals in the same position within the
acrylic imaging chamber for morphological correlation,
as described previously [19].
MRI
MRI measurements were conducted on a clinical 3 Tesla
scanner (MAGNETOM Skyra, Siemens Healthineers,
Erlangen, Germany) using a 16-channel wrist coil
(Siemens Healthineers, Erlangen, Germany). Mice were
positioned head-first in prone position. For the assess-
ment of tumor morphology and tumor volume as
morphology-based surrogate of tumor response, T2-
weighted MR images were acquired using a 2D Turbo
Spin Echo sequence (TR = 5470 ms, TE = 91 ms, in-
plane resolution 0.3 × 0.3 mm, matrix size 192 × 192,
slice thickness 1.5 mm). In addition, DW-MRI data sets
were acquired using a single shot echo planar imaging se-
quence (TR = 3200 ms, TE = 50 ms, FOV = 84 mm, acqui-
sition matrix = 64 × 64, reconstructed matrix = 128 × 128,
slice thickness 2 mm, 8 averages, time to acquisition
180 s; 3 b-values: b = 0 s/mm2/200 s/mm2/800 s/mm2).
Apparent diffusion coefficient (ADC) maps were calcu-
lated by voxel-wise least-squares fitting of the model
S bð Þ ¼ S0  e−bADC:
MRI data sets were analyzed on an external worksta-
tion using a dedicated, in-house written post-processing
software (PMI; Platform for Research in Medical
Imaging, version 0.4) [20]. For each measurement, a
multi-slice VOI was drawn manually over the entire
tumor. The median value inside this VOI was used to
calculate a representative tumor ADC value for statis-
tical analysis.
Fig. 1 Experimental protocol. 18F–FDG-PET/CT and MRI baseline scans were performed on day 0. Animals received either a BRAF and CDK4/6
inhibitor combination therapy (therapy group) or a volume-equivalent placebo (control group) administered daily over the course of 6 days.
Follow-up 18F–FDG-PET/CT and MRI scans were performed on day 7. Subsequent to follow-up imaging, animals were sacrificed. The tumors were
explanted to undergo the immunohistochemical analysis with regard to tumor microvascular density (CD31) and tumor cell proliferation (Ki-67)
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Immunohistochemistry
Three micrometer tissue sections were cut from the
formalin-fixed and paraffin-embedded tumor tissue and
stained with regard to microvascular density (CD31) and
tumor cell proliferation (Ki-67). After de-waxing and re-
hydration following standard procedures (pre-heating at
60 °C, washing in xylene substitute (Neo-Clear, Merck
KgaA, Darmstadt, Germany) and rehydration in a graded
series of ethanol (100, 95, 80, and 70%, respectively)
followed by double distilled water, antigen demasking
was performed by microwave irradiation at 600 W in a
0.1 M citrate buffer solution (pH 6.0). Tissue samples
were subsequently antibody-incubated at 4 °C over night
(antibodies: monoclonal rabbit anti-Ki-67 antibody; SP6,
Abcam ab16667 1:100, Cambridge, United Kingdom;
polyclonal rabbit anti-CD31 primary antibody; Abcam
ab28364 1:50, Cambridge, United Kingdom).
According to the manufacturer’s instructions, further
work-up of tissue samples was performed using the
EnVision + System HRP (DAB or AEC) (DAKO
Diagnostika, Hamburg, Germany) kit. Slides were coun-
terstained using Mayer’s Haemalaun (Merck KgaA,
Darmstadt, Germany) and covered with Kaiser’s Glycerin
Gelatine (Merck KgaA, Darmstadt, Germany). Results
were quantified as the number of positively stained nu-
clei (Ki-67) or positively stained microvessels (CD31) in
ten random fields at 200× magnification.
Statistical analysis
In this randomized placebo-controlled preclinical trial
the statistical analyses were performed using commer-
cially available statistics software (SPSS 23, IBM Corp.,
Armonk, NY). For intergroup comparisons of the
imaging and the immunohistochemical parameters, the
Mann-Whitney-U-test was applied. For intragroup com-
parisons between baseline (day 0) and follow-up (day 7),
a Wilcoxon signed-rank test was performed. Correla-
tions between the imaging and the immunohistochemi-
cal parameters were assessed by Spearman’s correlation
coefficient. Continuous variables were presented as
means with standard deviations. The confirmatory tests
were performed against a significance level α = 0.05 with
Bonferroni corrections.
Results
The experimental protocol was successfully completed
in n = 21 animals. There were no significant (p > 0.05)
intergroup differences between therapy and control
group in baseline TTL (TTLBaseline: 4.19 ± 0.97 vs.
3.70 ± 0.90; p = 0.193) and baseline ADC (ADCBaseline:
0.78 ± 0.10 × 10−3 mm2/s vs. 0.79 ± 0.10 × 10−3 mm2/s;
p = 0.754) as well as in metabolic (161.1 ± 86.5 mm3
vs. 217.9 ± 145.8 mm3; p = 0.464) and morphological
(94.6 ± 71.4 mm3 vs. 134.3 ± 89.0 mm3; p = 0.219)
tumor volumes.
18F–FDG-PET/CT
We observed a significant reduction of TTL under
therapy (TTLTherapy from 4.19 ± 0.97 to 3.19 ± 0.97;
p = 0.002). In the control group, TTL demonstrated
a non-significant increase from baseline to follow-up
(TTLControl from 3.70 ± 0.90 to 4.55 ± 0.91; p = 0.14).
Follow-up TTL values were significantly lower in the
therapy group (TTLFollow-up: 3.19 ± 0.97 vs. 4.55 ± 0.91;
p = 0.007). Moreover, ΔTTL (TTLFollow-up – TTLBase-
line) was negative and significantly lower in the
Fig. 2 PET/CT VOI Selection. a and b: coronal unenhanced CT without (a) and with (b) VOIs. c and d: Fused coronal PET/CT data sets without
(c) and with (d) VOIs. Note the tumor in the lateral flank (red asterisk). The liver is indicated by a white asterisk. To calculate the metabolic tumor
volume, a PET/CT-guided VOI surrounding the tumor was drawn. Background was determined in a VOI in the right liver lobe and the TTL was
calculated accordingly
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therapy compared to the control group (ΔTTLTherapy −
1.00 ± 0.53 vs. ΔTTLControl 0.85 ± 1.21; p < 0.001). The
metabolic tumor volume increased in the control group
(from 217.9 ± 145.8 mm3 on day 0 to 573.5 ± 294.7 mm3
on day 7; p = 0.008), while no significant change was ob-
served in the therapy group (from 161.1 ± 86.5 mm3 to
211.6 ± 139.4 mm3; p = 0.308). Metabolic tumor volumes
on follow-up were significantly higher in the control
than in the therapy group (573.5 ± 294.7 mm3 vs.
211.6 ± 139.4 mm3; p = 0.001). Figure 3 shows repre-
sentative 18F–FDG-PET/CT data sets from the ther-
apy and the control group. Individual TTL values and
metabolic tumor volumes at baseline and at follow-up
are provided in Table 1.
MRI
DW-MRI detected an increase in ADC under therapy
with a trend toward significance (ADCTherapy: from 0.78
± 0.10 × 10−3 mm2/s to 0.90 ± 0.13 × 10−3 mm2/s; p =
0.026). In the control group, the ADC showed a signifi-
cant decline (ADCControl: from 0.79 ± 0.10 × 10
−3 mm2/s
to 0.68 ± 0.06 × 10−3 mm2/s; p = 0.012). Follow-up ADC
values were significantly higher in the therapy group
(0.90 ± 0.13 × 10−3 mm2/s vs. 0.68 ± 0.06 × 10−3 mm2/s in
the control group; p < 0.001). Moreover, ΔADC (ADCFol-
low-up – ADCBaseline) was significantly elevated in the
therapy group (ΔADCTherapy 0.12 ± 0.14 × 10
−3 mm2/s;
ΔADCControl − 0.12 ± 0.06 × 10
−3 mm2/s; p < 0.001). Analo-
gously to the metabolic tumor volumes, the morphological
tumor volumes measured on T2w images significantly
increased in the control group (from 134.3 ± 89.0 mm3 to
381.9 ± 179.4 mm3; p = 0.008). In the therapy group, the
morphological tumor volumes showed a non-significant
increase between baseline and follow-up (from 94.6 ±
71.4 mm3 to 130.8 ± 91.3 mm3; p = 0.071). Figure 4 shows
representative MRI data sets from the therapy and the con-
trol group. Table 2 displays individual ADC values and the
morphological tumor volumes for the therapy and the con-
trol group. Figure 5 shows boxplot diagrams of ΔTTL and
ΔADC for the therapy and the control group.
Immunohistochemistry
Multiparametric immunohistochemistry revealed a sig-
nificantly lower microvascular density (CD31: 147 ± 48
vs. 287 ± 92; p = 0.001) and tumor cell proliferation (Ki-
67: 3718 ± 998 vs. 5389 ± 1332; p = 0.007) in the therapy
compared to the control group. Table 3 summarizes in-
dividual immunohistochemical values for both groups.
Figure 6 shows representative tumor sections from the
therapy and the control group.
Correlations between imaging and immunohistochemical
parameters
TTL demonstrated a good, significant correlation to
microvascular density (CD31, ρ = 0.79; p < 0.001) and
no significant correlation to the proliferation rate (Ki-
67, ρ = 0.33; p = 0.14). ADC showed a strong and highly
significant inverse correlation to microvascular density
(CD31, ρ = −0.80; p < 0.001) but no significant correl-
ation to proliferation (Ki-67, ρ = −0.42; p = 0.061).
Fig. 3 Axial PET/CT data sets of representative tumors from therapy and control group. Top row: 18F–FDG-PET/CT data sets. Bottom row: CT data
sets. a therapy group, baseline. b therapy group, follow-up. c control group, baseline. d control group, follow-up. Note the significantly
suppressed tumor glucose uptake following the 1-week BRAF and CDK 4/6 inhibitor combination therapy (b vs. a). Note the significant increase
in tumor glucose uptake and tumor volume in the control group (d vs. c)
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ΔTTL and ΔADC showed strong and significant in-
verse correlations (ρ = −0.75; p = 0.002).
Discussion
In the present study, we investigated 18F–FDG-PET/CT
and DW-MRI for the in vivo monitoring of a novel
BRAF and CDK4/6 inhibitor combination therapy in hu-
man melanoma xenografts in mice. Dual inhibition of
the MAPK signal pathway demonstrated significant anti-
angiogenic and anti-proliferative effects in the investi-
gated tumor model. The multimodal imaging protocol
allowed for the in vivo monitoring of tumor glucose
metabolism and tumor diffusivity, adding molecular and
functional information to the established morphology-
based assessments of tumor response.
Our results are in line with previous preclinical and
clinical studies investigating tumor response to targeted
MAPK signal pathway inhibition. Baudy et al. reported a
reduction in tumor glucose metabolism in A375 xeno-
grafts in mice following a BRAF (vemurafenib) and MEK
inhibitor (GDC-0973) combination therapy over the
course of 6 days [21]. However, the authors validated the
imaging results by tumor cell glucose transporter 1 and
MAPK pathway protein expression but not by immuno-
histochemical markers of microvascular density or
tumor cell proliferation. Analogously, combined BRAF
and MEK targeting (vemurafenib plus cobimetinib or
dabrafenib plus trametinib) lead to a significant reduc-
tion in tumor maximum standardized uptake value
(SUVmax) in patients with advanced melanoma with a
mean time to follow-up of 26 days [22]. 18F–FDG-PET
even provided predictive imaging biomarkers of therapy
response in the investigated patient population, with a
significant association of the change in SUVmax and
progression-free survival observed for the least respon-
sive tumor focus [22]. These studies underline the ap-
plicability and clinical significance of 18F–FDG-based
hybrid imaging for therapy monitoring in melanoma
under MAPK pathway inhibition. Providing a surrogate
of tumor cellularity, DW-MRI confirmed the 18F–FDG-
PET results and may thus be a suitable imaging modality
to allow for a multi-facetted tumor characterization
under targeted therapy. In experimental human BRAF-
mutant melanomas, DW-MRI was successfully used for
Table 1 Individual values for tumor glucose uptake and metabolic tumor volumes at baseline and follow-up
Number Groupa TTLBaseline TTLFollow-Up ΔTTL VolumeBaseline (mm
3) VolumeFollow-up (mm
3) ΔVolume (mm3)
1 T 5.63 4.83 −0.79 296.0 311.4 15.4
2 T 4.80 3.13 −1.67 86.8 50.4 −36.4
3 T 5.90 5.26 −0.64 56.1 162.7 106.6
4 T 3.72 2.65 −1.07 155.9 417.9 262.0
5 T 3.94 3.88 0.06 142.5 433.7 291.2
6 T 4.57 3.02 −1.55 230.8 185.2 −45.6
7 T 4.61 2.90 −1.71 112.8 78.2 −34.6
8 T 3.69 2.40 −1.29 162.7 118.0 −44.7
9 T 3.11 2.52 −0.59 332.0 392.0 60.0
10 T 3.59 2.46 −1.13 171.3 161.7 −9.6
11 T 4.14 2.93 −1.21 120.0 80.6 −39.4
12 T 2.57 2.29 −0.28 66.2 147.8 81.6
Mean ± SDb T 4.19 ± 0.97 3.19 ± 0.97 −1.00 ± 0.53 161.1 ± 86.5 211.6 ± 139.4 50.5 ± 117.9
13 C 4.34 4.06 −0.28 96.9 344.0 247.1
14 C 3.07 5.13 2.06 519.1 1192.3 673.2
15 C 5.62 5.50 −0.12 213.0 616.1 403.1
16 C 2.88 3.95 1.07 140.1 329.1 189.0
17 C 4.02 4.13 0.11 222.6 597.8 375.2
18 C 3.31 5.25 1.94 165.1 511.0 345.9
19 C 3.50 5.45 1.95 115.6 421.3 305.7
20 C 2.71 4.73 2.02 392.5 866.5 474.0
21 C 3.81 2.72 −1.09 96.0 283.1 187.1
Mean ± SDb C 3.70 ± 0.90 4.55 ± 0.91 0.85 ± 1.21 217.9 ± 145.8 573.5 ± 294.7 355.6 ± 153.3
aT = therapy group; C = control group
bSD = standard deviation
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the in vivo monitoring of a 4-day therapy with the MEK
inhibitor selumetinib [17]. Our results confirm the applic-
ability of both 18F–FDG-PET and DW-MRI for therapy
monitoring in the same tumors showing a strong, intrain-
dividual correlation between ΔTTL and ΔADC. This cor-
relation may be explained by the fact that a high tumor
cell density leads to restricted diffusion with low ADC
values and increased tumor glucose metabolism [23].
The addition of a MEK inhibitor to BRAF inhibitor
monotherapy proved to be a successful strategy to over-
come intrinsic or de novo BRAF inhibitor resistance in
BRAF-mutant melanoma [24]. However, resistance was
also reported for the BRAF/MEK inhibitor combination
therapy [25]. Therefore, novel compounds to be used in
combination with BRAF inhibitors are required to ad-
dress this clinical challenge and need to be investigated
in experimental and clinical studies. As a proof of
principle, the present study is a first approach to close
this gap of knowledge, exploring a selective CDK 4/6 in-
hibitor as novel combination compound for dual inhib-
ition of the MAPK signal pathway. Our preclinical
results add to the literature providing first evidence that
a novel BRAF and CDK 4/6 inhibitor combination ther-
apy may be an effective therapeutic regimen in BRAF-
mutant melanoma, with significant effects on tumor
glucose metabolism, tumor diffusivity, microvascular
density, and tumor cell proliferation. However, these
promising preclinical results require further validation in
future clinical studies. Selective CDK 4/6 inhibition was
shown to significantly improve progression-free survival
in patients with advanced breast cancer, but to date
there are no clinical data on combined BRAF and
CDK 4/6 inhibition [11, 26]. Our results indicate that
18F–FDG-PET/CT and DW-MRI may be applied for
non-invasive therapy guidance in clinical trials investi-
gating targeted MAPK pathway inhibition, adding
functional and molecular biomarkers of therapy
response to morphology-based response criteria.
Measurements of tumor radiotracer uptake and ADC
can easily be implemented in clinical routine staging
reports. Clinically, 18F–FDG-PET/CT is widely applied
for staging in advanced melanoma. The current
European Society for Medical Oncology guidelines
recommend CT or 18F–FDG-PET in advanced cutane-
ous melanoma (> pT3a) prior to surgical treatment
and sentinel lymph node biopsy [27]. The National
Comprehensive Cancer Network Clinical Practice
Guidelines in Oncology for Melanoma Version
01.2017 recommend CT and/or 18F–FDG-PET for
treatment response assessment in patients receiving
active non-surgical treatment (www.nccn.org). While
18F–FDG-PET/CT provides a comprehensive whole-
body tumor staging at a high spatial resolution, MRI
is mainly applied for the local staging of defined body
Fig. 4 Axial MRI data sets of representative tumors from therapy and control group. Top row: T2-weighted MRI data sets. Bottom row: DW-MRI
data sets. a: therapy group, baseline. b: therapy group, follow-up. c: control group, baseline. d: control group, follow-up. Note the significantly
increased tumor diffusivity under therapy (b vs. a) and the significantly decreased tumor diffusivity in the control group (d vs. c)
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Table 2 Individual values for tumor diffusivity and morphological tumor volumes at baseline and follow-up
Number Groupa ADCBaseline (mm
2x10−3/s) ADCFollow-up (mm
2x10−3/s) ΔADC (mm2x10−3/s) VolumeBaseline (mm
3) VolumeFollow-up (mm
3) ΔVolume (mm3)
1 T 0.84 0.84 0.00 163.0 166.3 3.3
2 T 0.88 1.16 0.28 25.7 33.5 7.8
3 T 0.74 0.72 −0.02 19.1 99.5 80.4
4 T 0.77 0.86 0.09 188.8 255.5 66.7
5 T 0.87 0.82 −0.05 88.5 281.1 192.6
6 T 0.62 0.84 0.22 154.9 107.7 −47.2
7 T 0.79 1.07 0.28 67.2 48.3 −18.9
8 T 0.71 0.87 0.16 38.7 50.8 12.1
9 T 0.66 0.83 0.17 232.5 264.1 31.6
10 T 0.73 0.81 0.08 62.0 123.0 61.0
11 T 0.76 1.07 0.31 48.9 31.9 −17.0
12 T 0.97 0.85 −0.12 45.6 107.9 62.3
Mean ± SDb T 0.78 ± 0.10 0.90 ± 0.13 0.12 ± 0.14 94.6 ± 71.4 130.8 ± 91.3 36.2 ± 63.2
13 C 0.85 0.77 −0.08 119.0 356.0 237.0
14 C 0.70 0.63 −0.07 320.6 777.6 457.0
15 C 0.86 0.69 −0.17 103.1 379.7 276.6
16 C 0.96 0.76 −0.20 81.5 212.9 131.4
17 C 0.78 0.63 −0.15 138.0 371.4 233.4
18 C 0.73 0.61 −0.12 109.0 292.9 183.9
19 C 0.87 0.71 −0.16 72.7 301.7 229.0
20 C 0.61 0.61 0.00 232.7 541.0 308.3
21 C 0.79 0.69 −0.10 31.8 203.5 171.7
Mean ± SDb C 0.79 ± 0.10 0.68 ± 0.06 −0.12 ± 0.06 134.3 ± 89.0 381.9 ± 179.4 247.6 ± 95.1
aT = therapy group; C = control group
bSD = standard deviation
Fig. 5 ΔTTL and ΔADC values in therapy and control group. Note the significant suppression of tumor glucose metabolism (a) as well as the
significant increase of tumor diffusivity under therapy (b)
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regions, e. g., for the detection of brain and liver metasta-
ses, and may therefore complement whole-body imaging
protocols for the longitudinal assessment of therapy re-
sponse [28]. State-of-the-art DW-MRI sequences, e. g., for
the brain or abdomen, can be acquired in less than 3 min
and may be integrated in standard MRI protocols without
significant prolongation of the acquisition time.
Limitations
The study is limited in several aspects. First, although all
efforts were made to maintain the same scanning position
between PET and MRI as well as between baseline and
follow-up, it cannot be fully excluded that the animals
were scanned in slightly different planes with potential ef-
fects on the semiquantitative parameters. Hybrid imaging
on an integrated PET/MRI scanner with simultaneous ac-
quisition of both modalities may improve consistency and
concordance of the PET and MRI results due to equalized
scanning conditions. Second, ex vivo immunohistochemi-
cal analysis was performed in selected cross-sections of
the tumor and may not necessarily correspond to the
whole-tumor VOI. Third, we investigated the BRAF and
CDK 4/6 inhibitor combination therapy over the course of
1 week but did not compare the combination therapy to
the BRAF inhibitor monotherapy. The comparison of the
different therapy regimens in the same tumor model and
a longer follow-up interval may provide additional insights
in tumor pathophysiology and time course of acquired re-
sistance under MAPK pathway inhibition. Fourth, due to
study design, immunohistochemical parameters were only
acquired on day 7 after follow-up imaging.
Table 3 Individual immunohistochemical parameters
Number Groupa CD31 Ki-67
1 T 166 4433
2 T 83 5831
3 T 212 3189
4 T 129 2649
5 T 222 2832
6 T 182 3820
7 T 79 4033
8 T 105 2912
9 T 100 2227
10 T 151 4306
11 T 179 4210
12 T 151 4177
Mean ± SDb T 147 ± 48 3718 ± 998
13 C 271 6801
14 C 336 6349
15 C 447 6489
16 C 191 3799
17 C 307 4562
18 C 358 4582
19 C 261 3379
20 C 284 5718
21 C 132 6824
Mean ± SDb C 287 ± 92 5389 ± 1332
aT = therapy group; C = control group
bSD = standard deviation
Fig. 6 Tumor cell proliferation and microvascular density in representative tumor sections. Left column: therapy. Right column: control. Top row:
proliferation (Ki-67). Bottom row: microvascular density (CD31). Note the significantly lower tumor proliferation (Ki-67) and tumor microvascular
density (CD31) in the therapy compared to the control group
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Conclusion
In conclusion, we demonstrated that a novel BRAF and
CDK 4/6 inhibitor combination therapy exhibits signifi-
cant anti-angiogenic and anti-proliferative effects in ex-
perimental human melanomas in mice and that the
according alterations in tumor pathophysiology can be
monitored non-invasively and in vivo by 18F–FDG-PET/
CT and DW-MRI. Co-targeting the MAPK pathway using
a BRAF and CDK 4/6 inhibitor combination therapy is a
novel approach to potentially overcome intrinsic or de
novo BRAF inhibitor resistance in BRAF-mutant melan-
oma and may be investigated in future clinical trials.
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